An Early Phase 1 interventional study of ZP6590, solution for injection and Placebo, solution for injection in Healthy Participants Study, Overweight and Obese Adults and First in Man Study to Evaluate Initial Safety, sponsored by Zealand Pharma. Recruiting at 1 site in Germany. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Zealand Pharma · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 338 studies in Obesity with a site in Germany — 75 open to participants now, 110 under way, 49 of them phase 3. Obesity · Germany.
Among the 338 studies in Obesity with a site in Germany, this one is the 189th largest by planned enrollment of the 276 interventional ones that give a count, is one of 49 that started in 2026, is one of 43 in phase 1, reaches primary completion later than 46 of the 109 other live ones, and was the 316th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →75 of the 338 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Germany, United States, Spain and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Germany, United States, Spain and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Diabetes Center · Sites in Germany
Ages 19–75
Technical University of Munich · Sites in Germany
Ages 18–60
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 60 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 27 · Phase 3 89 · Phase 4 12
First in 1998; this study’s year is marked. 49 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 160 across the 276 interventional studies, 165 across the 62 observational. Of the 198 that completed or were terminated, 32 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 338 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
38 of the studies in Obesity with a site in Germany that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 38 to your calendar (.ics) → With an account.
Among the 338 studies in Obesity with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults. The main questions it aims to answer are:
In the first Part of the study:
Participants will:
In the second Part of the study:
Participants will:
The main objective of this randomized, double-blind, placebo-controlled trial is to assess the safety and tolerability of drug ZP6590 as single ascending doses and multiple ascending doses in healthy participants living with normal weight, overweight and obesity.
In addition, the study will investigate the pharmacokinetics of the drug ZP6590.
The trial is divided in two parts:
SAD-Part 1: Participants will be administered a single subcutaneous dose of the drug ZP6590 or placebo and will have an observation period of 4 weeks.
MAD-Part 2: Participants will be administered multiple dosages of the drug ZP6590 or placebo for 6 or 12 weeks followed by an observation period of 6 weeks after last dosing.
After informed consent has been obtained, eligibility of the participants will be assessed during a screening visit.
SAD- and MAD-Part: Eligible participants will be admitted to the site in the morning on Day before dosing and will have ambulatory visits or remain under in-house conditions after dosing.
Safety evaluation for dose escalation:
The safety and exposure assessments of each cohort will take place before dose escalation to the next dose level will start.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's planned enrollment of 88 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SAD-Part:
MAD-Part:
Exclusion Criteria:
SAD-Part and MAD-Part:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZP6590 will be administered as single dose administration and as multiple dose administrations.
Drug: ZP6590, solution for injection
Placebo will be administered as single dose administration and as multiple dose administrations.
Drug: Placebo, solution for injection
Participants will receive single or multiple subcutaneous dose administrations of ZP6590.
Participants will receive single or multiple subcutaneous dose administrations of Placebo.
Safety and Tolerability
Incidence of treatment emergent adverse events (TEAEs) from first dose to end of trial
Time frame: Single ascending Dose (SAD)-Part: From Day 1 to Day 29 (4 weeks) Multiple ascending Dose (MAD)-Part: MAD-cohorts (6-Weeks): From Day 1 to Day 78 MAD-cohort (12-Weeks): Day 1 to Day 120
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Area under the plasma concentration versus time curve from 0 to infinity (AUCinf)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Area under the plasma concentration versus time curve from 0 to last (AUClast)
Time frame: SAD Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Peak Plasma Concentration (Cmax)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Time to Peak Plasma Concentration (Tmax)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Terminal rate constant (λz)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Terminal half-life (t½)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
Apparent volume of distribution during terminal phase (Vz/f)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following single subcutaneous injection
apparent total clearance of ZP6590 from plasma for SAD cohorts (CL/f)
Time frame: SAD-Part: From Day 1 to Day 29
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Area under the plasma concentration versus time curve from 0 to trough (AUCτ)
Time frame: MAD-Part: After 1st and 4th doses (6-Weeks and 12-Weeks Cohorts) and after 6th dose (12-Weeks Cohort), dosing interval in hours.
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Peak Plasma Concentration (Cmax)
Time frame: MAD-Part: After 1st and 4th doses (6-Weeks and 12-Weeks Cohorts) and after 6th dase (12-Weeks Cohort), dosing interval in hours
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Time to Peak Plasma Concentration (Tmax)
Time frame: MAD-Part: After 1st and 4th doses (6-Weeks and 12-Weeks Cohorts) and after 6th dase (12-Weeks Cohort), dosing interval in hours
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Trough concentration measured predose for MAD cohorts (Cτ)
Time frame: MAD-Part: After 2nd, 3rd, 4th, 5th doses (6-Weeks Cohorts and 12-Weeks Cohort) and 6th, 7th, 8th, 9th, 10th, 11th and 12th doses (12-Weeks Cohort)
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Area under the plasma concentration versus time curve from 0 to infinity (AUCinf)
Time frame: MAD-Part: After 6th (6-Weeks Cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Area under the plasma concentration versus time curve from 0 to last (AUClast)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Peak Plasma Concentration (Cmax)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Time to Peak Plasma Concentration (Tmax)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Terminal rate constant (λz)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Terminal half-life (t½)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Apparent volume of distribution during terminal phase (Vz/f)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Apparent total clearance of ZP6590 from plasma at steady state (SS) for MAD-cohorts (CLss/f)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
To investigate the pharmacokinetic properties of ZP6590 following multiple subcutaneous injections
Mean residence time of plasma ZP6590 concentration at steady state (SS) for MAD cohorts (MRTss)
Time frame: MAD-Part: After 6th (6-Weeks cohorts) and 12th (12-Weeks-Cohort) doses
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 13 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.